[The problem of rare cancers.]

Area of Science:

• Oncology
• Regulatory Science
• Health Policy

Background:

• Rare cancers represent over 20% of new malignant tumors in the EU, posing significant challenges due to their low incidence.
• Rarity complicates clinical decision-making, evidence generation, and healthcare organization, particularly outside specialized centers.
• Existing definitions for rare diseases and cancers impact regulatory approaches and industry interest in developing treatments.

Purpose of the Study:

• To address the challenges in clinical research and regulatory aspects for rare cancers.
• To highlight the importance of collaborative networks and flexible regulatory frameworks.
• To propose strategies for improving access to innovative diagnostics and therapies for rare cancer patients.

Main Methods:

• Review of recommendations from the European Union's Joint Action on rare cancers.
• Analysis of regulatory aspects, including orphan drug policies and market exclusivity.
• Examination of healthcare organization models, such as the 'hub-and-spoke' network.

Main Results:

• Collaborative clinical networks, operating on a 'hub-and-spoke' model, can enhance care quality and rationalize patient mobility.
• Regulatory acceptance of slightly less stringent evidence quality for rare cancers is crucial to avoid patient discrimination.
• Closer cooperation between regulatory bodies, patient communities, and flexible regulatory mechanisms can mitigate industry regulatory risk.

Conclusions:

• Establishing collaborative clinical networks is vital for improving rare cancer care and research.
• Regulatory frameworks must adapt to the unique challenges of rare cancers, balancing evidence standards with patient access.
• National-level initiatives, including compassionate use programs and updated rare disease laws, are essential for advancing rare cancer treatment in Italy.